Search
Amidosiarczanowe pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu, pochodne 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu, ich zastosowanie medyczne i sposób otrzymywania amidosiarczanowych pochodnych 4-(1-fenylo-1H-[1,2,3]triazol-4-ylo)-fenolu
Details
- Creators
- Property
- Politechnika Gdańska
- Supervisor unit
Legal protection
- Status
- Pending
- Patent granting institution
- WIPO
- Application number
- PCT/PL2018/000080 20-08-2018
- Verified by:
- Gdańsk University of Technology
Legal protection 239999
- Status
- Protected
- Patent granting institution
- Urząd Patentowy Rzeczpospolitej Polskiej
- Application number
- P.425970 18-06-2018
- Patent number
- 239999
- Verified by:
- Gdańsk University of Technology
Legal protection CA 3101768
- Status
- Protected
- Patent granting institution
- Urząd Patentowy Kanady
- Application number
- CA 3101768 20-08-2018
- Patent number
- CA 3101768
- Verified by:
- Gdańsk University of Technology
Legal protection US 11,939,303
- Status
- Protected
- Patent granting institution
- United States Patent and Trademark Office
- Application number
- US 17/252,703 20-08-2018
- Patent number
- US 11,939,303
- Verified by:
- Gdańsk University of Technology
Legal protection JP.7160387
- Status
- Protected
- Patent granting institution
- Japoński Urząd Patentowy
- Application number
- 2020-570953 20-08-2018
- Patent number
- JP.7160387
- Verified by:
- Gdańsk University of Technology
Legal protection EP.3790868
- Status
- Protected
- Patent granting institution
- Urząd Patentowy Rzeczpospolitej Polskiej
- Application number
- EP.18786433 20-08-2018
- Patent number
- EP.3790868
- Verified by:
- Gdańsk University of Technology
Oferty komercjalizacji
Oferta
New molecular entity (NME) that proved to be a very promising drug candidate in the treatment of hormone-dependent diseases, particularly cancers such as breast, ovary, prostate, endometrium, testes.
During the course of the research many beneficial biological properties were confirmed, including:
high overall anti-cancer activity in vivo: +50% inhibition of tumor growth was observed for the most promising compound, highly inhibitory activity against the molecular target in vivo (apparently full blockage in the cancer cells and liver), essential reduction of estradiol levels in the blood, high solubility and permeability in vitro and in vivo, safety: observably no side effects during the experiments on mice even for doses as high as 50 mg / kg / day.Application and audience
Recently, steroid sulfatase (STS) inhibitors have become promising drug candidates in the treatment of a wide spectrum of tumors. Cancer diseases are a critical medical problem - according to the International Agency for Research on Cancer and European Commission estimates in 2018, globally there were more than 18 million new cases (3 million in the European Union [EU]) and 9.5 million cancer-related deaths (1.4 million in the EU), which indicates that tumors are among the leading causes of death worldwide.
Innovative aspects and main features
The hormone biosynthesis pathway is a well-established target for the development of hormone-dependent cancer drugs. Anticancer therapies currently used often turn out to be unsatisfactory and result in the development of resistance, leading to relapses in tumor progression (e.g. in case of therapies based on aromatase inhibitors). In light of recent research STS is becoming a new interesting molecular target in the development of novel and effective hormone-dependent cancer treatment methods. In contrast to aromatase, the STS activity is present in most cancer cases (e.g. STS expression is detected in 90% of breast tumors). Furthermore, it has been noticed that STS mRNA levels in malignant tissues were higher than in normal breast tissues in 87% of tested patients.
seen 353 times